Evaluating Psychotropic Comedication Trends in Geriatric Bipolar Disorder

Bipolar disorder in older adults presents complex clinical dilemmas that demand sustained pharmacological management. While lithium remains the gold-standard mood stabilizer for long-term prophylaxis, real-world clinicians frequently augment it with additional agents. Understanding recent psychotropic comedication trends provides valuable insight into everyday prescribing patterns for aging individuals. A ten-year retrospective cohort study from the Netherlands investigated these exact medication trajectories among 166 older adults aged 55 years and above. The researchers analyzed comprehensive medical records between 2010 and 2019 using detailed Lifecharts to quantify treatment patterns over time.

The participants had a mean age of 67.4 years, representing a vulnerable demographic susceptible to drug accumulation and cognitive decline. Overall, the findings reveal that older adults received psychotropic comedications alongside maintenance lithium for 75.8% of the total observation period. Therefore, monotherapy represents the exception rather than the norm in late-life bipolar care. Consequently, clinicians must recognize that psychotropic polypharmacy persists throughout late-life management. In addition, these treatment regimens remained remarkably stable across the decade, showing that earlier escalation trends have plateaued. However, the sheer duration of adjunctive medication exposure raises critical questions regarding safety, treatment efficacy, and physical health outcomes in aging individuals.

High Prevalence of Polypharmacy Alongside Maintenance Lithium

Managing older adults with bipolar disorder often necessitates multi-agent strategies to address residual mood instability. In this cohort, patients spent more than three-quarters of their total follow-up time taking at least one adjunctive psychotropic drug. Specifically, antidepressants accounted for 31.6% of total observation time. This widespread antidepressant prescribing occurred despite ongoing debate regarding their long-term efficacy and switch risk in bipolar maintenance. Furthermore, atypical antipsychotics were prescribed for 25.9% of the follow-up period, providing mood stabilization and sedation.

Similarly, clinicians prescribed a second mood stabilizer for 18.4% of the follow-up duration. These secondary agents typically included anticonvulsants such as valproate or lamotrigine to bolster relapse prevention. Meanwhile, typical first-generation antipsychotics were utilized during 8.7% of the total observation time, reflecting their diminished role in modern geriatric practice. Importantly, these prescription proportions remained largely unchanged between 2010 and 2019. This stability indicates that clinical practices established during the preceding decade persisted without substantial disruption. Consequently, polypharmacy has become an entrenched maintenance strategy for geriatric psychiatric patients. Nevertheless, combining multiple neuroactive drugs substantially increases the burden of drug-drug interactions, anticholinergic toxicity, and metabolic complications in frail older adults.

Prolonged Benzodiazepine Exposure and Associated Clinical Risks

Among all comedication classes evaluated, benzodiazepines emerged as the most frequently prescribed drug category. Remarkably, patients received benzodiazepine prescriptions for 56.2% of the entire ten-year follow-up period. This extensive exposure directly contradicts international clinical practice guidelines, which strongly advise against long-term benzodiazepine administration in geriatric populations. Clinicians frequently initiate these agents during acute manic, depressive, or anxious exacerbations to restore sleep and reduce agitation. However, treatment frequently transitions into continuous, indefinite maintenance without structured re-evaluation or planned discontinuation.

Chronic benzodiazepine consumption in older adults carries substantial clinical hazards. In particular, age-related reductions in hepatic metabolism and renal clearance prolong drug elimination half-lives. As a result, older patients experience cumulative sedation, motor incoordination, and psychomotor impairment. Furthermore, extensive observational evidence links prolonged sedative use to increased risks of accidental falls, hip fractures, and traumatic brain injuries. Additionally, persistent exposure accelerates cognitive impairment and exacerbates existing memory deficits, which mimics or worsens underlying dementia. Therefore, the widespread, long-term prescription of benzodiazepines documented in this study underscores an urgent clinical challenge. Geriatric teams must actively implement deprescribing protocols to mitigate avoidable harm and prioritize safer behavioral sleep interventions.

The Rising Trajectory of Low-Dose Quetiapine Utilization

Although most psychotropic classes maintained steady prescribing rates across the decade, quetiapine exhibited a distinct, statistically significant upward trajectory. Specifically, prescriptions for quetiapine at doses below 50 mg daily increased significantly over the ten-year period. In 2010, patients received low-dose quetiapine for only 2.0% of their follow-up time. By 2019, this proportion escalated to 8.1% of total observation time. Clinicians predominantly prescribe these very low doses off-label as a sedative-hypnotic agent to treat insomnia and nocturnal restlessness.

This off-label practice generates significant clinical concern among geriatricians and psychopharmacologists alike. At doses below 50 mg daily, quetiapine acts primarily as a potent histamine H1 receptor antagonist rather than an effective mood stabilizer or antipsychotic. Consequently, the drug fails to deliver proven antimanic or antidepressant therapeutic efficacy at subtherapeutic dosages. Moreover, even low doses can induce meaningful adverse events, including morning sedation, orthostatic hypotension, cardiac conduction alterations, and metabolic dysregulation. In addition, frail older adults face elevated risks of anticholinergic side effects and fall-related injuries. Thus, substituting low-dose quetiapine for conventional sleep hygiene or structured psychotherapy introduces unnecessary pharmacologic hazards without robust evidence of long-term therapeutic benefit.

Clinical Recommendations and Deprescribing Strategies for Older Adults

The findings from this ten-year cohort emphasize the critical need for regular medication reviews in older patients with bipolar disorder. Because age-related physiological alterations reduce organ reserve, clinicians must routinely assess whether ongoing comedications remain clinically justifiable. Lithium monotherapy provides exceptional prophylactic protection when clinicians maintain serum levels within appropriate geriatric target ranges, typically between 0.4 and 0.7 mEq/L. Therefore, medical teams should view adjunctive agents as temporary stabilizing measures rather than permanent lifelong prescriptions.

To reduce polypharmacy, healthcare providers should establish structured deprescribing routines during periods of sustained mood euthymia. First, physicians must prioritize the gradual tapering of benzodiazepines, replacing them with cognitive behavioral therapy for insomnia. Second, practitioners should carefully re-evaluate off-label low-dose quetiapine, reserving antipsychotic therapy for validated clinical indications at therapeutic doses. Furthermore, physicians must monitor antidepressants continuously, considering deprescribing when depressive symptoms have resolved without subsequent recurrence. Interdisciplinary collaboration between psychiatrists, geriatricians, and clinical pharmacists ensures systematic monitoring of drug interactions, renal function, and cognitive status. Ultimately, rational psychotropic stewardship minimizes adverse drug events while safeguarding affective stability and overall quality of life for aging individuals.

Frequently Asked Questions

Why is the widespread use of benzodiazepines concerning in older adults?

Benzodiazepines significantly elevate the risk of motor impairment, accidental falls, hip fractures, and cognitive decline in older adults. Furthermore, age-related changes in drug metabolism prolong sedative effects, leading to daytime grogginess and paradoxical confusion. Clinical guidelines consistently recommend against long-term benzodiazepine prescribing, advising brief acute use only.

Why has low-dose quetiapine prescribing increased alongside lithium?

Clinicians frequently prescribe low-dose quetiapine off-label to manage insomnia and nighttime agitation in older adults. Between 2010 and 2019, its prescription duration quadrupled in this cohort. However, subtherapeutic doses act mainly as antihistamines without mood-stabilizing efficacy, while still causing daytime sedation, orthostatic hypotension, and potential metabolic disturbances.

How should clinicians approach psychotropic comedications in late-life bipolar disorder?

Clinicians should conduct regular medication reviews and actively pursue deprescribing during periods of sustained clinical stability. They must gradually taper nonessential sedatives and reserve adjunctive mood stabilizers or antipsychotics for clear clinical indications. In addition, optimizing geriatric lithium dosing and utilizing non-pharmacological interventions help minimize polypharmacy risks.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. Always consult a qualified healthcare provider for diagnosis and treatment recommendations. Refer to the latest local and national guidelines for clinical practice.

References

1. Paans O et al. Psychotropic comedication trends in long-term lithium treatment for older adults with bipolar disorder: A 10-year analysis. J Affect Disord. 2025 Jul 01. doi: 10.1016/j.jad.2025.03.091. PMID: 40120957.


2. Sajatovic M, Strejilevich SA, Gildengers AG, et al. A report on older-age bipolar disorder from the International Society for Bipolar Disorders Task Force. Bipolar Disord. 2015;17(7):689-704.


3. Dols A, Sienaert P, van Gerven H, et al. The prevalence and clinical correlates of complex polypharmacy in older patients with bipolar disorder. Int J Geriatr Psychiatry. 2020;35(7):728-735.